➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKesson
Colorcon
Boehringer Ingelheim
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,631,322

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,631,322
Title: Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
Abstract:Polymers of the monomer N-acryloylmorpholine having a single reactive moiety at one end of the polymer chain have the following structure: ##STR1## wherein --Z--X--Y is a polymer capping moiety, such as mercaptan, X represents a saturated residue of a linear or branched aliphatic series of the general structure --C.sub.r H.sub.2r -- in which r is an integer from 1 to about 12, Y is a reactive moiety and typically will be one of the reactive moieties commonly known in PEG chemistry, such as an --OH, --COOH, or --NH.sub.2 group, Z is a moiety that readily reacts to cap a polymer free radical, and n is an integer from about 6 to 280, which yields a number average molecular weight (\"M.sub.n \") of from about 1,000 to 40,000. The monofunctional polymer is a suitable alternative to monofunctional PEG for modification of substances having biological and biotechnical applications.
Inventor(s): Veronese; Francesco M. (Padua, IT), Schiavon; Oddone (Padua, IT), Caliceti; Paolo (Padua, IT), Sartore; Luciana (Marano Vic., IT), Ranucci; Elisabetta (Brescia, IT), Ferruti; Paolo (Milan, IT)
Assignee: Consiglio Nazionale delle Ricerche (IT)
Application Number:08/475,177
Patent Claims:1. A conjugate of preformed active polymeric N-acryloylmorpholine homopolymer and a substance selected from the group consisting of proteins, enzymes, polypeptides, drugs, dyes, nucleosides, lipids, and liposomes, in which the homopolymer is attached to the substance by an activated chain end by other than free radical polymerization.

2. The conjugate of claim 1 wherein the substance is selected from the group consisting of proteins and enzymes.

3. The conjugate of claim 1 wherein the substance is a polypeptide.

4. The conjugate of claim 1 wherein the substance is a drug.

5. The conjugate of claim 1 wherein the substance is a nucleoside.

6. The conjugate of claim 1 wherein the substance is a lipid.

7. The conjugate of claim 1 wherein the substance is a liposome.

8. The conjugate of claim 1 wherein the substance is superoxide dismutase.

9. The conjugate of claim 1 wherein the substance is asparaginase.

10. The conjugate of claim 1 wherein the substance is tyrosinase.

11. The conjugate of claim 1 wherein the substance uricase.

12. The conjugate of claim 1 wherein the substance is arginase.

13. The conjugate of claim 1 wherein the substance is catalase.

14. The conjugate of claim 1 wherein the substance is trypsine.

15. The conjugate of claim 1 wherein the substance is ribonuclease.

16. The conjugate of claim 1 wherein the substance is lipase.

17. The conjugate of claim 1 wherein the substance is doxorubicine.

18. The conjugate of claim 1 wherein the substance is amoxicillin.

19. The conjugate of claim 1 wherein the substance is distearoylphosphatidyl-ethanolamine.

20. The conjugate of claim 1 wherein the substance is dimethoxytrityl-deoxythymidine.

21. A biomaterial comprising an active polymeric N-acryloylmorpholine homopolymer attached to a surface, in which the homopolymer is attached to the substance by an activated chain end by other than free radical polymerization.

22. The biomaterial according to claim 21 wherein the surface is glass.

23. The biomaterial according to claim 21 wherein the surface is silica.

Details for Patent 5,631,322

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ⤷  Free Forever Trial Consiglio Nazionale delle Ricerche (IT) 2014-05-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
Express Scripts
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.